508316 CTAP - CAS 103429-32-9 - Calbiochem

508316
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Empirical FormulaCAS #
C₅₁H₆₉N₁₃O₁₁S₂103429-32-9

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
5.08316.0001
Retrieving availability...
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA highly potent octapeptide that acts as a selective and brain penetrating bioavailable µ opioid receptor antagonist (IC50 = 3.5 nM). Used in studies of reward systems and additions.
      Catalogue Number508316
      Brand Family Calbiochem®
      Synonymsµ opioid receptor antagonist, CTAP
      References
      ReferencesPerry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.
      Product Information
      CAS number103429-32-9
      FormOff-white solid
      Hill FormulaC₅₁H₆₉N₁₃O₁₁S₂
      Chemical formulaC₅₁H₆₉N₁₃O₁₁S₂
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetu Opioid receptpr
      Primary Target IC<sub>50</sub>3.5 nM
      Purity≥95% by HPLC
      Physicochemical Information
      Peptide SequenceD-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (2-7 disulfide bond)
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      CTAP - CAS 103429-32-9 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Perry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-October-2013 JSW
      Synonymsµ opioid receptor antagonist, CTAP
      DescriptionA highly potent octapeptide that acts as a selective and brain penetrating bioavailable µ opioid receptor antagonist (IC50 = 3.5 nM). Used in studies of reward systems and additions.
      FormOff-white solid
      CAS number103429-32-9
      Chemical formulaC₅₁H₆₉N₁₃O₁₁S₂
      Peptide SequenceD-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (2-7 disulfide bond)
      Purity≥95% by HPLC
      SolubilityH₂O
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesPerry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.